Karyopharm Therapeutics reported $-43626000 in EBITDA for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Abbott ABT:US $ 3042M 769M
Acceleron Pharma XLRN:US $ -69.47M 6.84M
Amgen AMGN:US $ 3228M 40M
Astrazeneca AZN:US $ 2784M 588M
AstraZeneca AZN:LN 2784M 588M
Avrobio Inc AVRO:US $ -32246000 1.17M
Bristol Myers Squibb BMY:US $ 5712M 33M
Eli Lilly And LLY:US $ 2437.5M 639.8M
Epizyme EPZM:US $ -62.82M 6.9M
GlaxoSmithKline GSK:LN 3660M 1034M
Johnson & Johnson JNJ:US $ 8192M 2043M
Karyopharm Therapeutics KPTI:US $ -43626000 5.19M
Macrogenics MGNX:US $ -50191000 12.69M
Mirati Therapeutics MRTX:US $ -78.98M 84.79M
Nektar Therapeutics NKTR:US $ -109.98M 3.32M
Novartis NVS:US $ 4837M 65M
Novartis NOVN:VX SF 4837M 65M
Pfizer PFE:US $ 10235M 2245M
Regeneron Pharmaceuticals REGN:US $ 1920.4M 1497.9M
Sangamo Biosciences SGMO:US $ -45.88M 0.57M
Takeda 4502:JP Y 238074M 153426M
Ultragenyx Pharmaceutical RARE:US $ -86.61M 6.96M
Xencor XNCR:US $ -39.31M 50.15M
YTE INCY:US $ 262.16M 92.39M